Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 457,500 shares, a growth of 90.3% from the December 15th total of 240,400 shares. Approximately 3.2% of the company’s shares are sold short. Based on an average daily volume of 3,640,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 32.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Virpax Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ VRPX opened at $0.35 on Thursday. The business’s fifty day simple moving average is $0.45 and its 200-day simple moving average is $0.73. Virpax Pharmaceuticals has a 12-month low of $0.29 and a 12-month high of $5.48.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.